SCHEMBL10102196

SCHEMBL10102196

COc1ccc(C2(c3ccccc3)C=Cc3c(c4c(c5ccccc35)-c3ccccc3CC4)O2)cc1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.33
MEN1 O00255 2/20 0.33
POLB P06746 1/20 0.33
OPRM1 P35372 1/20 0.33
OPRL1 P41146 1/20 0.33
EDNRB P24530 1/20 0.33
EDNRA P25101 1/20 0.33
MAPT P10636 5/20 0.32
ALDH1A1 P00352 3/20 0.32
KDM4E B2RXH2 2/20 0.32
KIF11 P52732 1/20 0.32
ACHE P22303 1/20 0.32
HPGD P15428 1/20 0.32
CASP1 P29466 1/20 0.32
MPI P34949 1/20 0.32
HSD17B10 Q99714 1/20 0.32
NPC1 O15118 2/20 0.32
RAB9A P51151 2/20 0.32
PKM P14618 1/20 0.32
HTT P42858 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL675539 0.98 MEN1 (0.34) KMT2AMEN1POLBEDNRBEDNRA
SCHEMBL10102331 0.94 MEN1 (0.34) KMT2AMEN1POLBEDNRBEDNRA
SCHEMBL10102380 0.93 LTA4H (0.38) KMT2AMEN1POLBEDNRBEDNRA
SCHEMBL13464675 0.91 MEN1 (0.31) KMT2AMEN1POLBEDNRBEDNRA
SCHEMBL12952418 0.91 MEN1 (0.31) KMT2AMEN1POLBEDNRBEDNRA
SCHEMBL14444797 0.90 DRD2 (0.34) KMT2AMEN1POLBOPRM1OPRL1
SCHEMBL13880499 0.90 MEN1 (0.33) KMT2AMEN1POLBOPRM1OPRL1
SCHEMBL14267914 0.90 MEN1 (0.34) KMT2AMEN1POLBEDNRBEDNRA
SCHEMBL10102351 0.88 EDNRA (0.43) EDNRBEDNRAALDH1A1HPGDNPC1
SCHEMBL10102344 0.88 ALDH1A1 (0.34) KMT2AMEN1POLBEDNRBEDNRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8308995-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2012-11-13 US disclosed
US-8308995-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2012-11-13 US disclosed
EP-2275418-B1 CHROMENE COMPOUND TOKUYAMA CORP (JP) 2012-10-17 EP disclosed
US-20120138876-A1 CHROMENE COMPOUND KASAI SOKO (JP) 2012-06-07 US disclosed
US-20120138876-A1 CHROMENE COMPOUND KASAI SOKO (JP) 2012-06-07 US disclosed
US-8147726-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2012-04-03 US disclosed
US-8147726-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2012-04-03 US disclosed
US-20110062396-A1 CHROMENE COMPOUND TOKUYAMA CORPORATION (JP) 2011-03-17 US disclosed
US-20110062396-A1 CHROMENE COMPOUND TOKUYAMA CORPORATION (JP) 2011-03-17 US disclosed
EP-2275418-A1 CHROMENE COMPOUND Tokuyama Corporation (JP) 2011-01-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120138876-A1 CHROMENE COMPOUND CHRM1, CBX8, CBX7 KMT2A 1084/4885MEN1 270/4885POLB 3905/4885
US-20110062396-A1 CHROMENE COMPOUND CDYL, NR0B1, NR1H2 KMT2A 3251/4885MEN1 1800/4885POLB 3631/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.